Speakers

Susanne Arnold, Justine Cooper, Robert DiPaola, B Mark Evers, Shridar Ganesan, C Darrell Jennings, Bridgette Kanz Schroader, Jill Kolesar, Philip Schwieterman, Paige Sininger, Sivakumaran Theru Arumugam, Barbara Thies, Thomas Tucker, Rachel Ware

Susanne Arnold, MD

Professor of Medicine
Associate Director, Clinical Research
Department of Oncology
Division of Internal Medicine
College of Medicine
Medical Oncologist
Markey Cancer Center
University of Kentucky
Lexington, Kentucky

Dr. Arnold has over thirteen years of experience in clinical and translational research in cancer therapeutics. In 2003, Dr. Arnold received the SWOG Young Investigator Award and was awarded the Shumate Professorship in Cancer Research in 2007, and the Buck Lung Chair in Lung Cancer Research in 2012. She has numerous research interests including the development of novel anti-cancer agents, such as AR-67, among others. In addition, she is the principal investigator of over 14 investigator-initiated clinical trials in lung and head and neck cancer, has authored 44 original manuscripts, trained over 20 fellows and countless residents in lung and head and neck cancer oncology. She serves as a clinical mentor for several post-doctoral students in pharmaceutical sciences and the medical oncology fellowship program. As the principal investigator of the Lung Cancer Research Initiative, funded by the Department of Defense, and the Marty Driesler Lung Cancer Project, funded by the HRSA and CDC, she has collaborated extensively with other clinicians, epidemiologists, behavioral and basic scientists, utilizing cancer registry data and accumulated field research in rural Appalachia to study populations at high risk of developing lung cancer. Her current research interests include development of novel therapeutics in solid tumors, drug development of nanotechnology-designed compounds and delivery formulations, the utilization of new drug combinations in lung and head and neck cancer, and the use of low-dose radiation as sensitizer of chemotherapy, in addition to the investigation of disparities in lung cancer incidence in Appalachian Kentucky and mechanism of development of lung cancer in this region.

Back to top

Justine Cooper, MS, CGC

Genetic Counselor
Markey Cancer Center
University of Kentucky
Lexington, Kentucky

Justine Cooper obtained her Bachelor of Arts degree from Miami University in Oxford, Ohio and her Master of Science degree in Genetic Counseling from the University of Texas Health Science Center in Houston, Texas. She completed the Cancer Prevention Research Training Program (CPRTP) at MD Anderson in 2010. Justine is a certified genetic counselor and is responsible for providing programmatic leadership for genetic counseling services at Markey Cancer Center. She is board certified by the American Board of Genetic Counseling.

Back to top

Robert DiPaola, MD

Dean
University of Kentucky College of Medicine
Lexington, Kentucky

Dr. DiPaola earned BS and MD degrees at the University of Utah, completed an internship and residency in internal medicine at Duke University Medical Center, and completed a fellowship in hematology-oncology at the University of Pennsylvania Hospital in Philadelphia.

With considerable experience in the area of translational research with a primary focus on the study of prostate cancer, he was one of the earliest investigators to target the degradation of bcl-2/apoptosis and autophagy/cancer metabolism in both the laboratory and clinic as a means to restore drug sensitivity in prostate cancer; and clinical studies that have had impact on standards of care, including recent studies published as senior author in high impact journals including the New England Journal of Medicine (2015) and Lancet (2016). His accomplishments in the area of translational research are also underscored by grants from the NIH, Department of Defense, ACS, and private foundations, as well as additional prior publications in other prominent journals including the JAMA, Cell, Arch Intern Med, Genes & Devel, Clinical Cancer Research, and the Journal of Clinical Oncology. He is currently Multi-PI of an NCI/NIH Therapeutics UM1 Grant with Ohio State and is a full member of multiple NCI/NIH committees, including the Investigational Drug Steering Committee and NCI/NIH IRG Subcommittee A (Parent Committee) for cancer centers review, of which he was elected Chair in August 2016.

He has also had considerable experience in leadership and administration: at Rutgers leading the growth, restructuring, and integration of an NCI-designated comprehensive cancer center as a full financial responsibility center within a large state University matrix; the creation and launch of a full clinical service line; and programmatic multidisciplinary research initiatives with an emphasis on building upon academic strengths bridging multiple schools and institutes.

At the University of Kentucky, he is leading efforts at state-wide campus expansions, new educational and research initiatives, executive leadership within the healthcare system and academic activities of the College of Medicine and the University.

Back to top

B Mark Evers, MD

Director, Markey Cancer Center
Professor and Vice Chair for Research
Department of Surgery
College of Medicine
University of Kentucky
Lexington, Kentucky

Since 2009 Dr. Evers has served as Director of Markey Cancer Center; Professor and Vice-Chair, Department of Surgery; Markey Cancer Foundation Endowed Chair; and Physician-in-Chief, Oncology Service Line with the University of Kentucky. He earned his MD from the University of Tennessee and performed his General Surgery residency at the University of Louisville. After completing a Gastrointestinal Physiology fellowship at the University of Texas Medical Branch, he joined the UTMB faculty. During his 20 years there he filled many roles, including the Robertson-Poth Distinguished Chair in General Surgery, Director of the Sealy Center for Cancer Cell Biology, and Director of the UTMB Comprehensive Cancer Center. Dr. Evers has received more than 30 awards and held several leadership positions in national organizations. His many research projects, which include a SPORE and NIH MERIT awards, have been continuously funded by the NIH for the past 20 years. He holds three patents, has authored more than 300 publications, and serves on several editorial and review boards.

Back to top

Shridar Ganesan, MD, PhD

Associate Director for Translational Science and Chief Molecular Oncology
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey

I came to The Cancer Institute of New Jersey in 2005 from the Dana-Farber Cancer Institute/Harvard Medical School where I was an instructor in medicine and staff physician. I started my medical training at Yale University, where I graduated from with both an MD and a PhD in cell biology. I then completed a medical residency at the Brigham and Women’s Hospital in Boston and served as a Chief Medical Resident. This was followed by a fellowship in medical oncology at the Dana-Farber Cancer Institute.

With a research interest in breast cancer biology and DNA repair, I am currently exploring how DNA repair defects in cancers can be exploited to develop novel effective treatments. I am also active in applying next-generation sequencing technology to identify specific genomic changes in cancers that can be therapeutically targeted. As a physician/scientist I both run a basic research laboratory focused on breast cancer biology and see patients in the Stacy Goldstein Breast Cancer Center. In the clinic, I work collaboratively with experts across multi-disciplines and have the opportunity to put theory into practice as we aim to develop the next generation of targeted treatments for breast cancer. Working with a team of radiation oncologists, surgical oncologists, nurses, social workers, genetic specialists and others, I help patients understand their specific disease and their treatment options so that they can make informed decisions. I am also an associate professor of medicine and pharmacology at Robert Wood Johnson Medical School.

I am the author or co-author of more than 40 publications and serve on the editorial board of the journal Frontiers in Molecular and Cellular Oncology.

Back to top

C Darrell Jennings, MD

Professor and Chair, Pathology and Laboratory Medicine
Senior Associate Dean, Education
University of Kentucky College of Medicine
Lexington, Kentucky

Dr. Jennings earned an MD from the University of Kentucky College of Medicine and completed residency at the UK Chandler Hospital in Lexington.

Clinical interests include anatomic pathology, clinical pathology, hematopathology, immunopathology, and transplantation.

Back to top

Bridgette Kanz Schroader, PharmD, MPA, BCOP

Clinical Pharmacist
UK HealthCare Pharmacy Services
Lexington, Kentucky

Bridgette grew up in Cleveland, Ohio and attended the University of Kentucky for her pre-pharmacy coursework. She graduated with honors from the University of Kentucky College of Pharmacy with her PharmD as well as Master of Public Administration. She is currently a Hematology/Oncology Clinical Pharmacist in the Markey Cancer Center, University of Kentucky.

During pharmacy school, she was involved in many student organizations and acted as Chief Pharmacy Intern for the UK Pharmacy Intern Program. At graduation, she was awarded the Daniel Reedy Capstone Award as well as an award for professional involvement outside the classroom. In her free time, Bridgette enjoys playing with her dog Rexi, traveling, playing volleyball and cheering on the Wildcats!

Back to top

Jill Kolesar, PharmD, MS, FCCP, BCPS

Co-Director, Molecular Tumor Board
University of Kentucky College of Pharmacy
Lexington, Kentucky

Dr. Jill Kolesar is Professor of Pharmacy at the University of Kentucky and holds administrative positions at the Markey Cancer Center as the Director of the Early Phase Clinical Trials Center, Co-Chair of the Molecular Tumor Board, and the Co-Leader of the Developmental Therapeutics Program. Jill received her BS in pharmacy at the University of Wisconsin and her Doctor of Pharmacy degree at the University of Texas Health Science Center in San Antonio, where she also completed a specialty practice residency in oncology/hematology and a fellowship in molecular oncology pharmacotherapy. She received an MS in Epidemiology with an emphasis in Genetic Epidemiology from the University of Wisconsin in 2016. After 15 years as a clinical pharmacist in the hematology clinic at Madison’s VA hospital, Dr. Kolesar transitioned her clinical practice to the UW Comprehensive Cancer Center where she co-chaired the Molecular Tumor Board, a multi-disciplinary group that reviews somatic mutations and recommends therapy targeted to those mutations for patients with cancer. Her research focuses on the drug development of anticancer agents with an emphasis on targeted therapies and biomarkers. She has authored more than 200 abstracts, research articles, and book chapters, and as a principal investigator she has received more than $1.5 million in research funding from the NCI, American Cancer Society and other sources. Jill has received teaching and research awards from local, national and international organizations including the Innovations in Teaching Award from the American Association of Colleges of Pharmacy.

Back to top

Philip Schwieterman, PharmD

Director of Oncology and Specialty Pharmacy
University of Kentucky College of Pharmacy
Lexington, Kentucky

Philip Schwieterman obtained his bachelors and doctorate of pharmacy degree from The Ohio State University and his Master in Health Administration from the University of Kentucky. He joined UK HealthCare in 2008 where he has served in a variety of staffing, clinical and administrative roles. He currently serves as the Director for Oncology and Infusion Pharmacy where he manages the operational, clinical, financial, and regulatory components of their oncology services.

Back to top

Paige Sininger, MBA

Director, Payer Contracting & Revenue Integrity
UK HealthCare
Lexington, Kentucky

Paige obtained her Bachelors in Accounting from the University of Kentucky and her Masters of Business Administration from Morehead State University. She joined UK HealthCare in 1999 where she has served in different administrative roles within the Revenue Cycle. Paige currently serves as the Director, Payer Contracting and Revenue Integrity. She manages the financial and operational aspects of contracting with third party payers as well as oversight of the Charge Description Master and Charge Capture Functions.

Back to top

Sivakumaran Theru Arumugam, PhD, FACMG

Associate Professor, Pathology and Laboratory Medicine
Director, Clinical Molecular and Genomic Pathology
University of Kentucky
Lexington, Kentucky

My name is Sivakumaran Theru Arumugam; I received my medical degree at All India Institute of Medical Sciences, New Delhi, India. I completed a fellowship in Clinical Molecular Genetics at Harvard Medical School in Boston. I am board certified by the American Board of Medical Genetics and Genomics in Clinical Molecular Genetics.

Back to top

Barbara Thies

Assistant Director, Patient Financial Services,
UK HealthCare
Lexington, Kentucky

Barbara joined UK HealthCare in 2004 in which she has served as the manager over financial counselors, financial assistance program and retro Medicaid. Barbara currently serves as the Associate Director over financial counseling, financial assistance program, retro Medicaid, patient balances, internal collection agency and vendor management for Patient Financial Services.

Back to top

Thomas Tucker, PhD, MPH

Associate Director, Cancer Prevention and Control
Markey Cancer Center
Associate Professor
College of Public Health
University of Kentucky
Lexington, Kentucky

Thomas C. Tucker is the Associate Director for Cancer Prevention and Control at the Markey Cancer Center and an Associate Professor in the College of Public Health. In addition, he is the Director of the Kentucky Cancer Registry. Dr. Tucker is the past President of the North American Association of Central Cancer Registries. He has also served as a member of the National Coordinating Council for Cancer Surveillance in the U.S. and the Canadian Council of Cancer Registries. Professor Tucker chaired the committee which established certification standards for population-based cancer surveillance programs in North America. He is actively engaged in population-based cancer research at the state, national and international levels. He is the Principle Investigator for the National Cancer Institute (NCI), Surveillance Epidemiology and End Results (SEER) program in Kentucky; and the Principal Investigator for the Centers for Disease Control and Prevention (CDC), National Program of Cancer Registries in Kentucky. Professor Tucker is an active contributor to the cancer control literature. His articles appear in publications such as: The Journal of the National Cancer Institute, Archives of Internal Medicine, Oncology, Primary Care and Cancer, The Journal of Rural Health and The Journal of Registry Management. He received the American Association of Community Cancer Center’s Award for outstanding contributions, the University of Kentucky’s O’Donnell Award for Outstanding Achievement as a Graduate Student, and the North American Association of Central Cancer Registry’s highest honor, the Calum Muir Award for lifetime contributions to the science of cancer surveillance. Dr. Tucker's research includes examination of variations in the patterns of care for stage III colorectal cancer in Kentucky, an exploration of human growth factors as they relate to colon cancer, studies of factor related to the high cervical cancer incidence and mortality in Appalachian Kentucky, and exploration of methods for estimating the completeness of case ascertainment in population-based cancer registries.

Back to top

Rachel Ware, MD

Associate Professor
Gynecology Oncology
Co-Director, Molecular Tumor Board
Markey Cancer Center
University of Kentucky
Lexington, Kentucky

My name is Rachel Ware Miller; I received my medical degree from the University of Kentucky, College of Medicine, Lexington. I then completed a fellowship at the University of Kentucky, Lexington.

I am board certified by the American Board of Obstetrics and Gynecology in Obstetrics and Gynecology and Gynecologic Oncology.

Back to top